Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Sep;104(1):251–257. doi: 10.1111/j.1476-5381.1991.tb12415.x

Mechanism of action of platelet activating factor in the pulmonary circulation: an investigation using a novel isotopic system in rabbit isolated lung.

J P Seale 1, S Nourshargh 1, P G Hellewell 1, T J Williams 1
PMCID: PMC1908255  PMID: 1786514

Abstract

1. Rabbit isolated lungs were perfused via the pulmonary artery with Tyrode solution containing 4.5% Ficoll and 0.1% bovine serum albumin at a constant rate of 20 ml min-1. Lung perfusate was drawn for alternating 5 min periods from two reservoirs, one containing 125I-albumin and the other unlabelled albumin to wash out the intravascular label. Microvascular 125I-albumin leakage was determined from the count remaining at the end of the washout phase with an external gamma scintillation probe. In addition, perfusion pressure was monitored continuously. Each experiment comprised 6 cycles over a total period of 60 min. 2. Infusion of platelet activating factor (PAF, 3 nmol min-1 for 10 min) resulted in microvascular 125I-albumin leakage, whereas lyso-PAF was without effect. During PAF infusions there was also an increase in perfusion pressure. Both the permeability and pressor effects of PAF were inhibited by the PAF antagonist L-652731. 3. Infusion of the thromboxane analogue U-46619 (0.6 nmol min-1 for 10 min) caused an increase in perfusion pressure but protein accumulation was not significantly different from that observed with control infusions. 4. Bolus injections of PAF (1 nmol) caused increases in perfusion pressure which were reduced by indomethacin, dazmegrel and BW 755C. Bolus injections of PAF, repeated at 30 min intervals caused reproducible pressor responses; however, repeated injections at 60 min intervals resulted in augmented responses. This augmentation did not occur in the presence of indomethacin. 5. Retrograde perfusion of PAF via the pulmonary vein induced increased perfusion pressure and microvascular 125I-albumin leakage.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
251

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer C. B., Page C. P., Paul W., Morley J., MacDonald D. M. Inflammatory characteristics of platelet activating factor (PAF-acether) in human skin. Br J Dermatol. 1984 Jan;110(1):45–50. doi: 10.1111/j.1365-2133.1984.tb07310.x. [DOI] [PubMed] [Google Scholar]
  2. Arnoux B., Denjean A., Page C. P., Nolibe D., Morley J., Benveniste J. Accumulation of platelets and eosinophils in baboon lung after paf-acether challenge. Inhibition by ketotifen. Am Rev Respir Dis. 1988 Apr;137(4):855–860. doi: 10.1164/ajrccm/137.4.855. [DOI] [PubMed] [Google Scholar]
  3. Arnoux B., Duval D., Benveniste J. Release of platelet-activating factor (PAF-acether) from alveolar macrophages by the calcium ionophore A23187 and phagocytosis. Eur J Clin Invest. 1980 Dec;10(6):437–441. doi: 10.1111/j.1365-2362.1980.tb02082.x. [DOI] [PubMed] [Google Scholar]
  4. Baranes J., Hellegouarch A., Le Hegarat M., Viossat I., Auguet M., Chabrier P. E., Braquet P. The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021. Pharmacol Res Commun. 1986 Aug;18(8):717–737. doi: 10.1016/0031-6989(86)90114-1. [DOI] [PubMed] [Google Scholar]
  5. Benveniste J., Henson P. M., Cochrane C. G. Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med. 1972 Dec 1;136(6):1356–1377. doi: 10.1084/jem.136.6.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Betz S. J., Henson P. M. Production and release of platelet-activating factor (PAF); dissociation from degranulation and superoxide production in the human neutrophil. J Immunol. 1980 Dec;125(6):2756–2763. [PubMed] [Google Scholar]
  7. Burhop K. E., Garcia J. G., Selig W. M., Lo S. K., van der Zee H., Kaplan J. E., Malik A. B. Platelet-activating factor increases lung vascular permeability to protein. J Appl Physiol (1985) 1986 Dec;61(6):2210–2217. doi: 10.1152/jappl.1986.61.6.2210. [DOI] [PubMed] [Google Scholar]
  8. Bussolino F., Camussi G., Aglietta M., Braquet P., Bosia A., Pescarmona G., Sanavio F., D'Urso N., Marchisio P. C. Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. J Immunol. 1987 Oct 1;139(7):2439–2446. [PubMed] [Google Scholar]
  9. Camussi G., Aglietta M., Malavasi F., Tetta C., Piacibello W., Sanavio F., Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. J Immunol. 1983 Nov;131(5):2397–2403. [PubMed] [Google Scholar]
  10. Camussi G., Pawlowski I., Saunders R., Brentjens J., Andres G. Receptor antagonist of platelet activating factor inhibits inflammatory injury induced by in situ formation of immune complexes in renal glomeruli and in the skin. J Lab Clin Med. 1987 Aug;110(2):196–206. [PubMed] [Google Scholar]
  11. Camussi G., Pawlowski I., Tetta C., Roffinello C., Alberton M., Brentjens J., Andres G. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. Am J Pathol. 1983 Jul;112(1):78–88. [PMC free article] [PubMed] [Google Scholar]
  12. Casals-Stenzel J., Muacevic G., Weber K. H. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. J Pharmacol Exp Ther. 1987 Jun;241(3):974–981. [PubMed] [Google Scholar]
  13. Chignard M., Le Couedic J. P., Vargaftig B. B., Benveniste J. Platelet-activating factor (PAF-acether) secretion from platelets: effect of aggregating agents. Br J Haematol. 1980 Nov;46(3):455–464. doi: 10.1111/j.1365-2141.1980.tb05993.x. [DOI] [PubMed] [Google Scholar]
  14. Christman B. W., Lefferts P. L., King G. A., Snapper J. R. Role of circulating platelets and granulocytes in PAF-induced pulmonary dysfunction in awake sheep. J Appl Physiol (1985) 1988 May;64(5):2033–2041. doi: 10.1152/jappl.1988.64.5.2033. [DOI] [PubMed] [Google Scholar]
  15. Coyle A. J., Urwin S. C., Page C. P., Touvay C., Villain B., Braquet P. The effect of the selective PAF antagonist BN 52021 on PAF- and antigen-induced bronchial hyper-reactivity and eosinophil accumulation. Eur J Pharmacol. 1988 Mar 22;148(1):51–58. doi: 10.1016/0014-2999(88)90453-0. [DOI] [PubMed] [Google Scholar]
  16. Findlay S. R., Lichtenstein L. M., Hanahan D. J., Pinckard R. N. Contraction of guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine. Am J Physiol. 1981 Sep;241(3):C130–C133. doi: 10.1152/ajpcell.1981.241.3.C130. [DOI] [PubMed] [Google Scholar]
  17. Goetzl E. J., Derian C. K., Tauber A. I., Valone F. H. Novel effects of 1-O-hexadecyl-2-acyl-sn-glycero-3-phosphorycholine mediators on human leukocyte function: delineation of the specific roles of the acyl substituents. Biochem Biophys Res Commun. 1980 Jun 16;94(3):881–888. doi: 10.1016/0006-291x(80)91317-0. [DOI] [PubMed] [Google Scholar]
  18. Grigorian G. Y., Ryan U. S. Platelet-activating factor effects on bovine pulmonary artery endothelial cells. Circ Res. 1987 Sep;61(3):389–395. doi: 10.1161/01.res.61.3.389. [DOI] [PubMed] [Google Scholar]
  19. Halonen M., Palmer J. D., Lohman I. C., McManus L. M., Pinckard R. N. Differential effects of platelet depletion on the physiologic alterations of IgE anaphylaxis and acetyl glyceryl ether phosphorylcholine infusion in the rabbit. Am Rev Respir Dis. 1981 Oct;124(4):416–421. doi: 10.1164/arrd.1981.124.4.416. [DOI] [PubMed] [Google Scholar]
  20. Halonen M., Palmer J. D., Lohman I. C., McManus L. M., Pinckard R. N. Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit. Am Rev Respir Dis. 1980 Dec;122(6):915–924. doi: 10.1164/arrd.1980.122.6.915. [DOI] [PubMed] [Google Scholar]
  21. Hamasaki Y., Mojarad M., Saga T., Tai H. H., Said S. I. Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution. Am Rev Respir Dis. 1984 May;129(5):742–746. doi: 10.1164/arrd.1984.129.5.742. [DOI] [PubMed] [Google Scholar]
  22. Handley D. A., Arbeeny C. M., Lee M. L., Van Valen R. G., Saunders R. N. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology. 1984 Dec;8(3-4):137–142. doi: 10.1016/0162-3109(84)90017-1. [DOI] [PubMed] [Google Scholar]
  23. Heffner J. E., Shoemaker S. A., Canham E. M., Patel M., McMurtry I. F., Morris H. G., Repine J. E. Acetyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. Role of thromboxane A2. J Clin Invest. 1983 Feb;71(2):351–357. doi: 10.1172/JCI110776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hellewell P. G., Williams T. J. A specific antagonist of platelet-activating factor suppresses oedema formation in an Arthus reaction but not oedema induced by leukocyte chemoattractants in rabbit skin. J Immunol. 1986 Jul 1;137(1):302–307. [PubMed] [Google Scholar]
  25. Humphrey D. M., McManus L. M., Satouchi K., Hanahan D. J., Pinckard R. N. Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues. Lab Invest. 1982 Apr;46(4):422–427. [PubMed] [Google Scholar]
  26. Hwang S. B., Lam M. H., Biftu T., Beattie T. R., Shen T. Y. trans-2,5-Bis-(3,4,5-trimethoxyphenyl)tetrahydrofuran. An orally active specific and competitive receptor antagonist of platelet activating factor. J Biol Chem. 1985 Dec 15;260(29):15639–15645. [PubMed] [Google Scholar]
  27. Imai T., Vercellotti G. M., Moldow C. F., Jacob H. S., Weir E. K. Pulmonary hypertension and edema induced by platelet-activating factor in isolated, perfused rat lungs are blocked by BN52021. J Lab Clin Med. 1988 Feb;111(2):211–217. [PubMed] [Google Scholar]
  28. Lellouch-Tubiana A., Lefort J., Simon M. T., Pfister A., Vargaftig B. B. Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration. Modulation by prostacyclin, platelet depletion, and selective antagonists. Am Rev Respir Dis. 1988 Apr;137(4):948–954. doi: 10.1164/ajrccm/137.4.948. [DOI] [PubMed] [Google Scholar]
  29. Lewis J. C., O'Flaherty J. T., McCall C. E., Wykle R. L., Bond M. G. Platelet-activating factor effects on pulmonary ultrastructure in rabbits. Exp Mol Pathol. 1983 Feb;38(1):100–108. doi: 10.1016/0014-4800(83)90102-8. [DOI] [PubMed] [Google Scholar]
  30. Lynch J. M., Lotner G. Z., Betz S. J., Henson P. M. The release of a platelet-activating factor by stimulated rabbit neutrophils. J Immunol. 1979 Sep;123(3):1219–1226. [PubMed] [Google Scholar]
  31. McManus L. M., Pinckard R. N. Kinetics of acetyl glyceryl ether phosphorylcholine (AGEPC)-induced acute lung alterations in the rabbit. Am J Pathol. 1985 Oct;121(1):55–68. [PMC free article] [PubMed] [Google Scholar]
  32. Morley J., Page C. P., Paul W. Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. Br J Pharmacol. 1983 Nov;80(3):503–509. doi: 10.1111/j.1476-5381.1983.tb10722.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. O'Flaherty J. T., Wykle R. L., Miller C. H., Lewis J. C., Waite M., Bass D. A., McCall C. E., DeChatelet L. R. 1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants. Am J Pathol. 1981 Apr;103(1):70–78. [PMC free article] [PubMed] [Google Scholar]
  34. Pirotzky E., Page C. P., Roubin R., Pfister A., Paul W., Bonnet J., Benveniste J. PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils. Microcirc Endothelium Lymphatics. 1984 Feb;1(1):107–122. [PubMed] [Google Scholar]
  35. Sanjar S., Aoki S., Boubekeur K., Chapman I. D., Smith D., Kings M. A., Morley J. Eosinophil accumulation in pulmonary airways of guinea-pigs induced by exposure to an aerosol of platelet-activating factor: effect of anti-asthma drugs. Br J Pharmacol. 1990 Feb;99(2):267–272. doi: 10.1111/j.1476-5381.1990.tb14692.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stimler N. P., O'Flaherty J. T. Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. Am J Pathol. 1983 Oct;113(1):75–84. [PMC free article] [PubMed] [Google Scholar]
  37. Vargaftig B. B., Ferreira S. H. Blockade of the inflammatory effects of platelet-activating factor by cyclo-oxygenase inhibitors. Braz J Med Biol Res. 1981 Jul;14(2-3):187–189. [PubMed] [Google Scholar]
  38. Warren J. S., Mandel D. M., Johnson K. J., Ward P. A. Evidence for the role of platelet-activating factor in immune complex vasculitis in the rat. J Clin Invest. 1989 Feb;83(2):669–678. doi: 10.1172/JCI113931. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES